SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.

Yumi Takiyama; Bessho R; Maeda Manami; Kuralay Atageldiyeva; Tsuyoshi  Yanagimachi; Jun Honjo; Yukihiro Fujita; Atsuko Abiko; Yuichi  Makino; Masakazu Haneda

SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.

Yumi Takiyama, Bessho R, Maeda Manami, Kuralay Atageldiyeva, Tsuyoshi Yanagimachi, Jun Honjo, Yukihiro Fujita, Atsuko Abiko, Yuichi Makino, Masakazu Haneda

Department of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Original language	English
Title of host publication	SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.
Publisher	American Diabetes Association Inc.
Pages	A136-A136
Publication status	Published - Jun 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Takiyama, Y., R, B., Manami, M., Atageldiyeva, K., Yanagimachi, T., Honjo, J., Fujita, Y., Abiko, A., Makino, Y., & Haneda, M. (2014). SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes. In SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes. (pp. A136-A136). American Diabetes Association Inc..

SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes. / Takiyama, Yumi; R, Bessho; Manami, Maeda et al.
SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.. American Diabetes Association Inc., 2014. p. A136-A136.

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Takiyama, Y, R, B, Manami, M, Atageldiyeva, K, Yanagimachi, T, Honjo, J, Fujita, Y, Abiko, A, Makino, Y & Haneda, M 2014, SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes. in SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.. American Diabetes Association Inc., pp. A136-A136.

@inproceedings{6548a32885094cdca0a8f779588498d1,

title = "SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.",

author = "Yumi Takiyama and Bessho R and Maeda Manami and Kuralay Atageldiyeva and Tsuyoshi Yanagimachi and Jun Honjo and Yukihiro Fujita and Atsuko Abiko and Yuichi Makino and Masakazu Haneda",

year = "2014",

month = jun,

language = "English",

pages = "A136--A136",

booktitle = "SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.",

publisher = "American Diabetes Association Inc.",

address = "United States",

}

TY - GEN

T1 - SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.

AU - Takiyama, Yumi

AU - R, Bessho

AU - Manami, Maeda

AU - Atageldiyeva, Kuralay

AU - Yanagimachi, Tsuyoshi

AU - Honjo, Jun

AU - Fujita, Yukihiro

AU - Abiko, Atsuko

AU - Makino, Yuichi

AU - Haneda, Masakazu

PY - 2014/6

Y1 - 2014/6

M3 - Conference contribution

SP - A136-A136

BT - SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.

PB - American Diabetes Association Inc.

ER -